Medication info

Pregabalin Capsule 150 mg (Pregabalin)

Prescription medicationApproval withdrawn
Ingredient · strength
Pregabalin›Strength being verified
Manufacturer / importer
Korea United Pharm (Co., Ltd.)
Appearance
A hard capsule with a white upper part and a white lower part containing white or light yellow powder.
Packaging
Domestic: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle Export: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle, 60 capsules (10 capsules/PTPX6)
Approval status
Approval withdrawn

MFDS item code 201109146 · Approved 2011.10.25

This product's status changed to Approval withdrawn on 2023.05.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be gradually withdrawn over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Additional dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The additional dose refers to a supplemental dose administered once. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with decreased renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Korea United Pharm (Co., Ltd.)

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for peripheral and central neuropathic pain in adults, as an adjunctive treatment for partial seizures in epilepsy, and for the treatment of fibromyalgia.

Dosage and Administration

Adult dosage

This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: A starting dose of 150 mg per day may be administered. Based on the response and tolerability of each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be gradually withdrawn over an interval of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose adjustment based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Additional dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The additional dose refers to a supplemental dose administered once. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with decreased renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior. If you experience signs of depression, mood changes, or unusual behavior while taking this drug, consult your doctor immediately. Patients with allergies to any component of this medication or specific genetic lactose intolerance disorders should not take it. Diabetic patients may need dose adjustments of blood glucose control medications due to weight gain. If symptoms of angioedema occur, stop the medication immediately. Elderly patients should be cautious due to risks of falls or injuries from dizziness or drowsiness. Temporary blurred vision or changes in vision can occur, and if symptoms persist, consult a doctor. When stopping this medication, withdrawal symptoms such as insomnia, headache, nausea, and anxiety may appear, so it should be gradually adjusted under medical guidance. There is a risk of drug abuse or dependence, so mental health status and drug use history should be disclosed to healthcare providers for close monitoring. Patients with reduced kidney function may require dose adjustments, and those with heart disease must consult a physician before taking it. There is a higher risk of respiratory depression when combined with other central nervous system depressants, so caution is advised. Pregnant women should avoid taking this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Nursing mothers should discuss with their doctor whether to discontinue breastfeeding or the medication, as this drug may pass into breast milk. This medication can cause dizziness and drowsiness, so caution is required when performing hazardous activities like driving or operating machinery. In case of overdose, symptoms such as confusion, drowsiness, or depression may occur, and treatment such as hemodialysis may be necessary if needed. Keep out of reach of children, and avoid transferring to other containers. If severe rashes, fever, or difficulty breathing occur, discontinue use and notify healthcare professionals immediately.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 193 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • agitation
  • pain
  • excessive sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • reduced respiratory function
  • rhinitis
  • neutropenia
  • increased appetite
  • appetite loss
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • restlessness
  • mood fluctuations
  • emotional dysregulation
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • reduced sensation
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • fasciculations
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • bradykinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • reduced oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme
  • delirium
  • paralysis
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • seizures
  • exacerbation of convulsions
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • bloody stools
  • ataxia
  • speech disorders
  • sensory abnormalities
  • memory impairment
  • attention deficit

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is also important to store it at room temperature between 15 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a white upper part and a white lower part containing white or light yellow powder.

Package unit

Domestic: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle Export: 10 capsules/bottle, 30 capsules/bottle, 60 capsules/bottle, 60 capsules (10 capsules/PTPX6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.